引用本文:张潇菡,徐炳欣,赵 艳,安文峰.丹参多酚酸对中青年脑梗死患者血清炎性因子及血管内皮功能的影响[J].中国临床新医学,2019,12(9):967-971.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1513次   下载 1398 本文二维码信息
码上扫一扫!
分享到: 微信 更多
丹参多酚酸对中青年脑梗死患者血清炎性因子及血管内皮功能的影响
张潇菡,徐炳欣,赵 艳,安文峰
461000 河南,许昌市中心医院药学部(张潇菡,徐炳欣,赵 艳),神经内科(安文峰);461000 河南,许昌市心血管药物临床研究重点实验室(徐炳欣)
摘要:
[摘要] 目的 探讨丹参多酚酸对中青年脑梗死患者血清炎性因子及血管内皮功能的影响,为临床脑梗死疾病的治疗提供参考。方法 前瞻性纳入150例中青年脑梗死患者,以随机数字表法分为观察组和对照组,每组75例。对照组患者给予常规脑梗死二级预防治疗,观察组患者在此基础之上联合应用丹参多酚酸。记录两组治疗前后血清白介素-6(IL-6)、白介素-17(IL-7)及超敏C反应蛋白(hs-CRP)等炎性因子水平,以治疗前后血浆内皮素-1(ET-1)、一氧化氮(NO)及血管内皮生长因子(VEGF)水平变化评价患者血管内皮功能。采用神经功能量表(NIHSS)评价患者治疗前后神经功能。随访6个月,比较两组不良事件发生率及药品不良反应发生情况。结果 两组治疗前IL-6、IL-17、hs-CRP、ET-1、NO、VEGF、NIHSS水平比较差异无统计学意义(P>0.05);治疗后,两组IL-6、IL-17、hs-CRP、ET-1、NIHSS水平均显著低于治疗前(P<0.05),NO、VEGF水平显著高于治疗前(P<0.05),且观察组IL-6、IL-17、hs-CRP、ET-1、NIHSS水平显著低于对照组(P<0.05),NO、VEGF水平显著高于对照组(P<0.05);两组不良事件总发生率及药品不良反应总发生率比较差异无统计学意义(P>0.05)。结论 丹参多酚酸能够显著降低中青年脑梗死患者的促炎性因子水平,改善患者血管内皮功能,且安全性好。
关键词:  丹参多酚酸  脑梗死  炎性因子  血管内皮功能  中青年患者
DOI:10.3969/j.issn.1674-3806.2019.09.09
分类号:R 741.05
基金项目:河南省医学科技攻关项目(编号:201602372);许昌市重大科技专项项目(编号:20180113031)
Effects of salvianolic acid on serum inflammatory factors and vascular endothelial function in young and middle-aged patients with cerebral infarction
ZHANG Xiao-han, XU Bing-xin, ZHAO Yan, et al.
Department of Pharmacy, Xuchang Central Hospital, Henan 461000, China
Abstract:
[Abstract] Objective To investigate the effects of salvianolic acid on serum inflammatory factors and vascular endothelial function in young and middle-aged patients with cerebral infarction, and to provide reference for the treatment of cerebral infarction. Methods One hundred and fifty young and middle-aged patients with cerebral infarction were prospectively enrolled. According to the method of random number table, the patients were divided into observation group and control group, with 75 cases in each group. The patients in the control group were given secondary prevention and treatment of cerebral infarction, while the patients in the observation group received the same treatment as the control group plus salvianolic acid. The levels of serum inflammatory factors including interleukin-6(IL-6), interleukin-17(IL-17) and hypersensitive C-reactive protein(hs-CRP) were recorded in the two groups before and after treatment. The changes of plasma endothelin-1(ET-1), nitric oxide(NO) and vascular endothelial growth factor(VEGF) levels before and after treatment were used to evaluate the vascular endothelial function. Neurological function was assessed with the National Institute of Health Stroke Scale(NIHSS) before and after treatment. After a follow-up of 6 months, the incidence rates of adverse events and adverse drug reactions were compared between the two groups. Results There were no significant differences in the levels of IL-6, IL-17, hs-CRP, ET-1, NO, VEGF and NIHSS between the two groups before treatment(P>0.05). The levels of IL-6, IL-17, hs-CRP, ET-1 and NIHSS after treatment were significantly lower than those before treatment in the two groups(P<0.05), and the levels of NO and VEGF were significantly higher than those before treatment(P<0.05). The levels of IL-6, IL-17, hs-CRP, ET-1 and NIHSS in the observation group were significantly lower than those in the control group(P<0.05). The levels of NO and VEGF in the observation group were significantly higher than those in the control group(P<0.05). There were no significant differences in the incidence rates of adverse events and adverse drug reactions between the two groups(P>0.05). Conclusion Salvianolic acid can significantly reduce the levels of pro-inflammatory factors in young and middle-aged patients with cerebral infarction, and improve the vascular endothelial function. Salvianolic acid is safe for the patients.
Key words:  Salvianolic acid  Cerebral infarction  Inflammatory factors  Vascular endothelial function  Young and middle-aged patients